|
Mark J. Gabrielson is a co-founder, director, and Chief Executive Officer of Pulmatrix Inc., a Cambridge, Massachusetts developer of proprietary aerosol inhalants designed to control respiratory infectious disease. Mr. Gabrielson has twenty-eight years of experience in pharmaceuticals and biopharmaceutical company formation and development. Following graduation from Princeton University, he held a sequence of commercial assignments over a twelve year period at SmithKline Beecham. During the period 1990-1999, Mr. Gabrielson was a General Partner of Prince Ventures LP, a private venture capital firm specializing in healthcare investing. Subsequently, Mr. Gabrielson co-founded and developed a series of emerging companies, including Pulmatrix. | 